Biotech Stocks with High Momentum Scores

Dianthus Therapeutics Inc. (DNTH) has seen a 90% surge in the past month due to positive Phase 2 trial results for its lead asset, claseprubart (DNTH103), in generalized myasthenia gravis. The stock's Momentum score has surged from 31.69 to 88.24 over the past 7 days. Korro Bio Inc. (KRRO) has soared in Benzinga’s Momentum rankings by 50.26 points, from 22.39 to 72.65, due to the company's recently secured Orphan Drug Designation for its lead RNA-editing therapy, KRRO-110. Centessa Pharmaceuticals PLC (CNTA) has seen a 48.75 point jump in its Momentum score, from 38.07 to 86.82, with a 42.85% spike over the past week alone.